Dr. Sara Gutiérrez-Enríquez is a Molecular Geneticist with 20 years of experience in the field of Human Genetics. She completed her PhD in Genetics at Autonomous University of Barcelona before moving on to a Marie Curie postdoctoral fellowship in DNA Repair and Cancer at International Agency for Research on Cancer in Lyon, France and in Hereditary Cancer in Hospital de la Santa Creu i Sant Pau, Barcelona. She was awarded with a Miguel Servet Contract, a prestigious program for incorporating clinical researchers in centers of the Spanish National Health System.

Her fields of expertise are Hereditary Breast and Ovarian Cancer (HBOC) and Radiogenomics. Her research is focused on improving genetic testing of HBOC through greater reliance on RNA-based genetic diagnosis and personalizing radiotherapy by deciphering the genetic susceptibility underlining the radiotherapy-induced normal tissue toxicity.

She has been accredited in Clinical Genetics by the Spanish Association of Human Genetics (AEGH). Dr. Sara Gutiérrez-Enríquez is member of the steer committee of ENIGMA international consortium (Evidence-based Network for Interpretation of Germline Mutant Alleles), which aims to develop statistical and laboratory methods to evaluate variants of uncertain clinical significance in known and suspected breast cancer predisposition genes.

She joined the Committee for the Interpretation of Genetic Variants in the Working Group of Predisposition to Cancer, which is part of the National IMPaCT-Genomic Project, 2022, and she is Member of the Publication Committee of the REQUITE European Consortium project (Validating predictive models of radiotherapy toxicity to improve quality-of-life and reduce side-effects in cancer survivors. Grant agreement ID: 601826).